China Pharma Holdings, Inc.
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- China Pharma Holdings, Inc. (NYSE American: CPHI) develops, manufactures, and markets generic and branded pharmaceutical products for human use in China, focusing on high-incidence and high-mortality diseases through dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions; its core portfolio includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and treatments targeting central nervous system conditions, cerebral-cardiovascular ailments, anti-infectives, respiratory issues, digestive disorders, and comprehensive healthcare solutions. The company operates primarily in the People's Republic of China, serving hospitals, medical professionals, retail pharmacies, and consumers via GMP-certified manufacturing facilities in Haikou, Hainan province, where it maintains its headquarters; founded in 1999, it emphasizes research and development to innovate formulations and expand distribution networks amid a competitive generic drug market. Recent developments include the completion of all redemptions under its $5.25 million Convertible Promissory Note with Streeterville Capital by December 2024, strengthening its financial position for growth initiatives; entry into an at-the-market equity offering program in December 2024 enabling up to $600,000 in capital raises; a 1-for-10 reverse stock split effective April 15, 2025, to meet NYSE American listing requirements following board and shareholder approvals; and ongoing advancements such as Phase I trial completion for an antibiotic, regulatory approvals for generic cholesterol and hepatitis drugs, and plans for a dry eye disease therapeutic device launch in early 2025.
China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity
China Pharma (NYSE:CPHI) & Acerus Pharmaceuticals (OTCMKTS:ASPCF) Financial Comparison
China Pharma (NYSE:CPHI) Shares Down 1% – What’s Next?
Critical Review: Galera Therapeutics (NASDAQ:GRTX) versus China Pharma (NYSE:CPHI)
China Pharma (NYSE:CPHI) Stock Price Down 10.2% – Should You Sell?
From Pandemic Innovation to Global Collaboration: Taiwan's TCM Shines at CPHI Frankfurt 2025
Thermo Fisher Scientific Showcases Enhanced Accelerator™ Drug Development Capabilities and OpenAI Strategic Collaboration at CPHI Frankfurt 2025
West Synchrony™ Prefillable Syringe System Launches at CPHI: Redefining a system-level solution for drug delivery
Defence Therapeutics to Attend CPHI Worldwide in Frankfurt, October 28-30, 2025
China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
IFF Pharma Solutions Brings Next-Gen Excipient Innovations to CPHI Japan 2025
China Pharma Holdings, Inc. Completes Full Redemptions Under Convertible Note Agreement with Streeterville
China Pharma Announces the Entry of "At-The-Market" Equity Offering
West Wins Heart of Pharma Award at 2024 CPHI Pharma Awards
West to Attend and Showcase Industry Leadership in Packaging and Containment at CPHI Worldwide Conference
Thermo Fisher Scientific Showcases Expanded Biopharma Services, Capabilities and Innovations at CPHI Milan 2024
Stevanato Group Will Introduce Its Large-Volume Vertiva® 10mL On-Body Delivery System Platform for Injectable Therapies at CPHI Milan
China Pharma Holdings, Inc. expects to launch its Dry Eye Disease Therapeutic Device in the first quarter of 2025
China Pharma Holdings Inc. Announces 1-for-5 Reverse Stock Split
China Pharma Holdings, Inc. Announced the Completion of Third Party Testing of Dry Eye Disease Therapeutic Device